Structures for clinical follow-up: Newborn screening

Journal of Inherited Metabolic Disease

Volumn 30, Issue 4, 2007, Pages 600-605

  Howell, Rodney ^a   Engelson, Gilian ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GALACTOSYLCERAMIDASE;

CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CYSTIC FIBROSIS; DECISION MAKING; FABRY DISEASE; FOLLOW UP; FUNDING; GLOBOID CELL LEUKODYSTROPHY; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; MEDICAL SOCIETY; NEWBORN SCREENING; PHENYLKETONURIA; PRACTICE GUIDELINE;

COMMUNITY HEALTH SERVICES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT WELFARE; INFANT, NEWBORN; NEONATAL SCREENING; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; PUBLIC HEALTH;

EID: 34548507228     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-007-0674-z     Document Type: Conference Paper

References (15)

1. Academy of Pediatrics (2000) Serving the family from birth to the medical home: A report from the Newborn Screening Task Force convened in Washington DC, May 10-11, 1999. Pediatrics 106: 383-427.
2. Alexander D, Hanson JW (2006) NICHD Research Initiative in Newborn Screening. Ment Retard Dev Disabil Res Rev 12: 301-304.
3. Editorial (2007) What is the Human Variome Project? Nat Genet 39: 423.
4. Hanson JW, Engelson GH, Howell RR (2007) Newborn screening research activities at the National Institutes of Health. American College of Medicine Genetics 2007 Annual Clinical Genetics Meeting, Abstract 118.
5. Hoff T, Hoyt A, Therrell B, Ayoob M (2006) Exploring barriers to long-term follow-up in newborn screening programs. Genet Med 8: 563-570.
6. Hoff T, Hoyt A (2006) Practices and perceptions of long-term follow-up among state newborn screening programs. Pediatrics 117: 1922-2929.
7. James PW, Levy HL (2006) The clinical aspects of newborn screening: importance of newborn screening follow-up. Ment Retard Dev Disabil Res Rev 12: 246-254.
8. Mandl KD, Feit S, Larson C, Kohane IS (2002) Newborn screening program practices in the United States: Notification, research and consent. Pediatrics 109: 269-273.
9. McKay KO, Waters DL, Gaskin KJ (2005) The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr 147: S47-S50.
10. Newborn Screening and Genetics Advisory Group (2007) Newborn Screening Long-term Follow-Up Assessment. Association of Maternal and Child Health Programs Report: 1-9.
11. Puryear M, Weissman G, Watson M, Mann M, Strickland B, van Dyck PC (2006) The regional genetic and newborn screening service collaboratives: The first two years. Ment Retard Dev Disabil Res Rev 12: 288-292.
12. Rinaldo P, Zafari S, Tortorelli S, Matern D (2006) Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. Ment Retard Dev Disabil Res Rev 12: 255-262.
13. Saavedra-Matiz C, Orsini J, Morrissey M, et al (2007) Implementation of newborn screening for Krabbe disease in New York state program. American College of Medicine Genetics 2007 Annual Clinical Genetics Meeting, Abstract 8.
14. Spada M, Pagliardini S, Yasuda M, et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79: 31-40.
15. Watson MS, Mann, MY, Lloyd-Puryear MA, Rinaldo, P, Howell RR (2006) Newborn screening: Toward a uniform screening panel and system. Genet Med 8: 1S-250S.